MétaCan
Menu
← Back to cohort

Comparative eligibility of metastatic pancreatic adenocarcinoma (MPA) patients for first-line palliative intent FOLFIRINOX (FIO) versus nab-paclitaxel plus gemcitabine (NG).

2014· article· en· W2747247135 on OpenAlexaffabout
Winson Y. Cheung, Daniel J. Renouf, Howard J. Lim, Renata D’Alpino Peixoto

Bibliographic record

VenueJournal of Clinical Oncology · 2014
Typearticle
Languageen
FieldMedicine
TopicPancreatic and Hepatic Oncology Research
Canadian institutionsBC Cancer Agency
Fundersnot available
KeywordsMedicineGemcitabineFOLFIRINOXInternal medicinePerformance statusRegimenUnivariate analysisBilirubinSurgeryCancerOncologyIrinotecanMultivariate analysis

Abstract

fetched live from OpenAlex

e15264 Background: The ACCORD and MPACT trials demonstrated superiority of FIO and NG over gemcitabine alone, respectively, in the treatment of MPA. In the absence of a direct comparison between these regimens, it is unclear whether FIO or NG is superior. Because both trials had stringent yet different inclusion criteria, our aim was to determine the proportion of MPA patients (pts) who would be potentially eligible for first-line palliative intent FIO vs. NG in routine clinical practice. Methods: Consecutive pts diagnosed with MPA from 2000 to 2011, referred to any 1 of 5 regional cancer centers in British Columbia, Canada and who initiated palliative chemotherapy with gemcitabine were reviewed. Clinicopathological variables and treatment outcomes were retrospectively collected and compared among groups. For this study, eligibility criteria for each regimen were based on those described in the respective phase III trials. Results: A total of 473 pts were identified: median age was 66 years (range 34–89) and 258 (55%) were men. Only 25% of pts would be eligible for FIO as compared to 45% for NG. The main reasons for ineligibility to FIO were age >/= 75 years (19%), ECOG performance status (PS) >/= 2 (57%), and bilirubin > 1.5 times upper limit of normal (ULN) range (18%). The main reasons for ineligibility to NG were ECOG PS >/= 3 (15%), bilirubin > ULN (25%), and cardiac dysfunction (14%). Median overall survival (OS) for the entire cohort treated with gemcitabine was 5.8 months (95% CI 5.4-6.2). On univariate analyses, eligible pts for FIO had longer median OS than ineligible pts (8.6 vs. 4.7 months, p<0.001). Pts eligible for NG also had longer median OS than those deemed ineligible (6.7 vs 4.9 months, p=0.008). After accounting for ECOG PS in the multivariate model, eligibility for either FIO or NG no longer predicted for better OS. Conclusions: In this population-based analysis, almost twice as many MPA pts would be eligible for NG than FIO. The longer OS observed in the FIO-eligible population likely reflects the exclusion of ECOG PS 2 pts. Accurate assessment of PS in MPA pts can facilitate treatment decision making and help with the selection between FIO and NG.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.006
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.002
Threshold uncertainty score0.009

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0020.006
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.340
GPT teacher head0.546
Teacher spread0.205 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations2
Published2014
Admission routes2
Has abstractyes

Explore more

Same venueJournal of Clinical Oncology→Same topicPancreatic and Hepatic Oncology Research→French-language works237,207→